US Stock MarketDetailed Quotes

SGMO Sangamo Therapeutics

Watchlist
  • 1.880
  • -0.080-4.08%
Close Nov 22 16:00 ET
  • 1.880
  • 0.0000.00%
Post 20:01 ET
392.26MMarket Cap-2647P/E (TTM)

Sangamo Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Sangamo Therapeutics Q3 2024 Earnings Date

Currency：USDNov 12, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
25.07M
49.41M
+24.34M
Beat Est.
+166.77%
+425.77%
+97.08%
EPS
-0.04
0.04
+0.08
Beat Est.
+93.24%
+106.78%
+200.25%
Analyst Rating
Buy

Nov 23, 2024

Sangamo Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 31.500M--
--2024/Q4-- / 10.317M--
Nov 12, 20242024/Q349.412M / 25.071M--
Aug 6, 20242024/Q2356.000K / 8.260M--
May 9, 20242024/Q1481.000K / 6.361M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 31.500M--
--2024/Q4-- / 10.317M--
Nov 12, 20242024/Q349.412M / 25.071M--
Aug 6, 20242024/Q2356.000K / 8.260M--
May 9, 20242024/Q1481.000K / 6.361M--

Unlock Free Earnings Estimates

Sangamo Therapeutics Earnings Reports

  • Sangamo Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 12 16:09 ET

  • Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER 2024 FINANCIAL RESULTS

    Nov 12 16:06 ET

  • Sangamo Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 6 16:07 ET

  • Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2024 FINANCIAL RESULTS

    Aug 6 16:06 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 23, 2024

    Buy

    • Buy

      60.00%

    • Hold

      40.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data

    Investment Theme Gene Editing
    Gene Editing
    Intraday+0.82%